$1.43
0.0%
Downside
Day's Volatility :4.67%
Upside
4.67%
46.5%
Downside
52 Weeks Volatility :67.31%
Upside
38.89%
Period | Compass Therapeutics Inc. | Index (Russel 2000) |
---|---|---|
3 Months | 9.16% | 0.0% |
6 Months | -25.52% | 0.0% |
1 Year | -37.83% | 0.0% |
3 Years | -64.07% | -22.3% |
Market Capitalization | 196.8M |
Book Value | $1.06 |
Earnings Per Share (EPS) | -0.35 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1770.0% |
Return On Assets TTM | -20.58% |
Return On Equity TTM | -30.05% |
Revenue TTM | 850.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -54.5M |
Diluted Eps TTM | -0.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.42 |
EPS Estimate Next Year | -0.51 |
EPS Estimate Current Quarter | -0.09 |
EPS Estimate Next Quarter | -0.1 |
What analysts predicted
Upside of 459.44%
Sell
Neutral
Buy
Compass Therapeutics Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Compass Therapeutics Inc. | 58.89% | -25.52% | -37.83% | -64.07% | -64.07% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Compass Therapeutics Inc. | NA | NA | NA | -0.42 | -0.3 | -0.21 | NA | 1.06 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Compass Therapeutics Inc. | Buy | $196.8M | -64.07% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Compass Therapeutics Inc.
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 74.9%
Orbimed Advisors, LLC
Adage Capital Partners Gp LLC
Blackstone Inc
BlackRock Inc
Rock Springs Capital Management LP
HHG PLC
compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond
Organization | Compass Therapeutics Inc. |
Employees | 32 |
CEO | Dr. Thomas J. Schuetz M.D., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.43
-4.03%
Keyarch Acquisition Corp
$1.43
-4.03%
Connexa Sports Technologies Inc
$1.43
-4.03%
Us Value Etf
$1.43
-4.03%
First Wave Biopharma Inc
$1.43
-4.03%
Global X Msci Next Emerging
$1.43
-4.03%
Fat Projects Acquisition Corp
$1.43
-4.03%
Capital Link Global Fintech
$1.43
-4.03%
Applied Uv Inc
$1.43
-4.03%